XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration Agreements (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Feb. 29, 2024
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Collaboration revenue $ 1,115 $ 57    
Ono Pharmaceutical Co. | License        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Remaining performance obligation, timing of termination     90 days  
Remaining performance obligation, amount     $ 5,400  
Collaboration revenue 800 0    
Remaining performance obligation, variable consideration amount     217,500  
Contract with customer, liability     $ 2,000  
Ono Pharmaceutical Co. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-03-01 | License        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Remaining performance obligation, expected timing of satisfaction, period     6 months  
Ono Pharmaceutical Co., Research Plan | License        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Remaining performance obligation, variable consideration amount     $ 7,000  
Contract with customer, liability     3,400  
Ono Pharmaceutical Co., Option | License        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Contract with customer, liability     $ 2,000  
ImmunoGen | Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Remaining performance obligation, amount       $ 2,000
Collaboration revenue $ 300 $ 100